| Patient | Barbara Jordan |
|---|---|
| Date of birth | 1982-02-21 |
| Identifiers | MRN HR-ML030-SYN; SSN (made up) 000-30-6852 |
| Document date | 2026-06-29 |
| Author | Evangeline Moss, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood. [S]
Ms. Jordan returns six weeks after her second ocrelizumab half-dose. During the first infusion she had a scratchy throat that settled when the infusion was slowed; the second infusion went without a reaction. She has had no infections, cold sores, or diarrhea. Physical therapy started four weeks ago through a second provider, after the first service could not offer a date; she has had six sessions and does her home program most days, and she now uses a rollator at home for longer distances. Summer has brought heat sensitivity: her legs feel heavier on hot afternoons and recover when she cools down, and she has started using a cooling vest. She gets up once a night or less. Her mood is steady. [S]
| Element | Detail |
|---|---|
| Infusions | Mild throat irritation with the first, settled by slowing; none with the second |
| Infections | None |
| Physical therapy | Started four weeks ago through a second provider; six sessions |
| Heat | Legs heavier on hot afternoons, recover with cooling |
| Mood | PHQ-9 3 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon fatigue, worse in the heat; no fever |
| Gastrointestinal | Negative | No diarrhea or abdominal pain |
| Genitourinary | Negative | Up once a night or less; no burning |
| Integumentary | Negative | No rash or cold sores |
| Neurological | Positive | Temporary heaviness of the legs in the heat; no new symptom lasting more than a day |
| Psychiatric | Negative | Mood steady |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-03-02 | active | S |
| Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated | One tablet three times a day | Oral route | 2026-03-16 to 2026-04-20 | completed | S |
| Baclofen 10 mg oral tablet, one tablet three times a day | One tablet three times a day | Oral route | 2026-04-20 | active | S |
| Mirabegron 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center | 300 mg on day 1 and day 15 (given), then 600 mg every 6 months | Intravenous route | 2026-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-29 | Body height | 173 | cm | S |
| 2026-06-29 | Body weight | 83.5 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 74 | /min | S |
| 2026-06-29 | Respiratory rate | 16 | /min | S |
| 2026-06-29 | Body temperature | 36.8 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-29 | Leukocytes [#/volume] in Blood by Automated count | 5.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-29 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 2026-06-29 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-29 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-29 | CD19 cells [#/volume] in Blood | 3 | /uL | Expected to be depleted after an anti-CD20 therapy | Low | S |
| 2026-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-35 U/L | Normal | S |
| 2026-06-29 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 118/74, pulse 74; temperature 36.8 °C |
| Neurological | Spastic gait with a cane, as before; modified Ashworth 1+ in both legs; EDSS 6.0; timed 25-foot walk 11.1 seconds |
| Skin | No rash |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine | resolved | confirmed | G35.D | S — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts. |
| Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis | active | confirmed | G35.B1 | S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts. |
| Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls | active | confirmed | R26.89 | S — Synthetic modern coding anchored to her documented cane. |
| Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual | active | confirmed | N31.9 | S — Synthetic; common in multiple sclerosis. No public source describes her bladder. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No relapse; heat-related pseudo-relapse explained |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Completed today | EDSS 6.0; timed 25-foot walk 11.1 seconds |
| Medication safety | Infusion reactions and infections | Each infusion, and every visit | Completed today | Mild throat irritation with the first infusion, settled by slowing; none with the second; no infections since |
| Laboratory | Blood count with absolute lymphocytes | Before the first dose, then before each dose | Completed today | White cells 5.9, lymphocytes 1.4, hemoglobin 13.4, platelets 248; CD19 3 per microliter (depleted, expected) |
| Laboratory | Liver tests | Before the first dose, then with symptoms and before each dose | Completed today | ALT 20 U/L |
| Laboratory | Hepatitis B surface antibody after vaccination | One to two months after the series in someone on immune therapy | Completed today | Protective level after two doses |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 1+ on baclofen 10 mg three times a day |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Nocturia once or less; blood pressure 118/74 on mirabegron |
| Referral | Falls, walking aids and physical therapy | Every visit | Completed today | Physical therapy started four weeks ago through a second provider; rollator at home; no falls |
| Self-management | Fatigue and heat sensitivity | Every visit | Completed today | Heat sensitivity; cooling vest started |
| Laboratory | 25-hydroxyvitamin D | At baseline, 8 to 12 weeks after repletion, then yearly | Completed today | 34 ng/mL after repletion |
| Imaging | Bone density | Once for reduced mobility and earlier steroid courses; repeat by risk | Due | At the preventive visit |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 months and with any change | Completed today | PHQ-9 3 |
| Examination | Concentration and word-finding | At intake, then yearly or with concern | Completed today | No concern raised by her; lectures and writing unaffected |
| Medication safety | Breast cancer screening (ocrelizumab label: standard screening) | Every two years from 40 | Due | Mammogram to be ordered at the preventive visit |
Goal progress:
Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026)
Follow-up: Preventive visit in seven weeks with bone density and the mammogram order. Re-baseline brain MRI and review in four months, before the 600 mg dose. Next scheduled visit 2026-08-17: periodic adult preventive visit. [S]